Home page >> Companies Profiles

Companies Profiles

Sponsors & Exhibitors 2023

Presidential Sponsors

Headquartered in Basel, Switzerland, Roche is a leader in research-focused healthcare with combined strengths in pharmaceuticals and diagnostics. Roche is the world’s largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and neuroscience. Roche is also the world leader in in vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management. Roche’s personalised healthcare strategy aims at providing medicines and diagnostics that enable tangible improvements in the health, quality of life and survival of patients.

For more information, please visit roche.com

At AbbVie, we set our sights on a future where vision lasts a lifetime. With a legacy of 75 years in eye care, we’re proud to offer 125 eye care products that help to preserve and protect vision for patients around the world. We treat conditions from the front to the back of the eye, including glaucoma, ocular surface disease and retinal diseases.

Platinum Sponsors

Iveric Bio is a science-driven biopharmaceutical company focused on the discovery and

development of novel treatments for retinal diseases with significant unmet medical needs. The Company is committed to having a positive impact on patients’ lives by delivering high-quality, safe and effective treatments designed to address debilitating retinal diseases including earlier stages of age-related macular degeneration. For more information on the Company, please visit www.ivericbio.com.

Bayer is a global enterprise with core competencies in the life science fields of health care and nutrition. Its products and services are designed to benefit people by supporting efforts to overcome the major challenges presented by a growing and aging global population.

Our vision of helping patients with exudative retinal disease see a better life is central to how we shape the future of ophthalmology through extensive research, global collaboration and needs-led innovation and technology.

Gold Sponsor

Apellis is a global biopharmaceutical company leveraging courageous science, creativity, and compassion to deliver life-changing medicines.

At Apellis, we are committed to developing transformative therapies for people living with Geographic Atrophy (GA) by regulating complement, a part of the body’s immune system.

Our work is rooted centrally at C3, which is the only target in the complement cascade that addresses all three pathways that can drive disease. Targeting C3 has broad platform potential to treat many diseases such as GA, where there are currently no treatment options available.

Company details

Apellis Switzerland GmbH, Zählerweg 10, 6300 Zug,


Email: medinfo@apellis.com

Websites: www.apellis.com; www.geographicatrophy.eu


Heidelberg Engineering GmbH

Max-Jarecki-Str. 8

69115 Heidelberg


Phone: +49 6221 6463 0

Fax: +49 6221 6463 340

Email: information@heidelbergengineering.com

URL: www.heidelbergengineering.com

Heidelberg Engineering continuously optimizes imaging and healthcare IT technologies to provide ophthalmic diagnostic solutions that empower clinicians to improve patient care. Uncompromising quality and education play a large part in fostering the diagnostic confidence that has become synonymous with the global brand. The growing product portfolio combines these core technologies: confocal microscopy, scanning lasers and optics, optical coherence tomography (OCT), real-time image processing and analytics, multimodal image management solutions (PACS), electronic medical records (EMR) and large-scale data analysis.

Outlook Therapeutics is a pre-commercial biopharmaceutical company working to develop and launch ONS-5010 / LYTENAVA™ (bevacizumab-vikg) as the first FDA-approved ophthalmic formulation of bevacizumab for use in retinal indications, including wet AMD, DME and BRVO. The U.S. Food and Drug Administration accepted Outlook Therapeutics’ Biologics License Application (BLA) for ONS-5010 to treat wet AMD on October 27, 2022. The FDA set a Prescription Drug User Fee Act (PDUFA) goal date of August 29, 2023. If ONS-5010 is approved, Outlook Therapeutics expects to commercialize it as the first and only FDA-approved ophthalmic formulation of bevacizumab for use in treating retinal diseases in the United States, United Kingdom, Europe, Japan, Greater China and other markets. Outlook Therapeutics’ BLA submission for ONS-5010 is as a new BLA under the PHSA 351(a) regulatory pathway.

If ONS-5010 is approved, the Company expects to commercialize it through best-in-class partnerships. To date, Outlook Therapeutics has manufacturing partnerships with Fujifilm Diosynth Biotechnologies and Ajinomoto Biopharma Services to provide product manufacturing in their best-in-class cGMP global manufacturing facilities.

Outlook Therapeutics has also executed a supply agreement for a best-in-class pre-filled ophthalmic syringe that will provide both ease-of-use for clinicians and add to ONS-5010’s potential safety profile over the current unapproved therapies that have caused problems related to syringe malfunction, contamination, etc.

Outlook Therapeutics intends to create goodwill and acceptance among payors, retinal specialists and patients by offering excellent value in an FDA-approved ONS-5010.

For more information, please visit www.outlooktherapeutics.com.

REGENXBIO Inc. is a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy. Our gene therapy product candidates are designed to deliver functional genes, enabling the production of therapeutic proteins or antibodies that are intended to impact disease. Through a single administration, gene therapy has the potential to provide long-lasting effects and improved patient outcomes. We have developed a broad pipeline of gene therapy programs using our NAV® Technology Platform. We believe this platform forms a strong foundation for our current programs, and with our ongoing research and development, we expect to continue to expand the platform.

Wisepress.com, Europe’s leading conference bookseller, attend around 200 conferences every year. We have an extensive range of books and journals relevant to the themes of this conference available at our booth. We also have a comprehensive range of STM titles available on our online bookshop. Follow us on Twitter @WisepressBooks.   

Add Your Heading Text Here